Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the completion of the sale, the chief financial officer now owns 13,000 shares of the company's stock, valued at $265,330. This represents a 20.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.59, for a total value of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.

Enliven Therapeutics Stock Down 2.1 %

NASDAQ:ELVN traded down $0.46 on Friday, reaching $21.00. 347,272 shares of the company's stock traded hands, compared to its average volume of 237,554. The firm has a market cap of $1.03 billion, a PE ratio of -11.05 and a beta of 1.04. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03. The stock has a 50-day simple moving average of $21.87 and a 200-day simple moving average of $23.90.

Remove Ads

Analyst Ratings Changes

Several research firms have issued reports on ELVN. Robert W. Baird boosted their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a report on Friday, November 15th. BTIG Research started coverage on Enliven Therapeutics in a research note on Friday, December 13th. They set a "buy" rating and a $42.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $38.25.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds have recently bought and sold shares of the business. FMR LLC increased its holdings in shares of Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after buying an additional 199,692 shares during the last quarter. Polar Capital Holdings Plc grew its position in Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after acquiring an additional 1,739,668 shares in the last quarter. Vanguard Group Inc. grew its position in Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after acquiring an additional 55,283 shares in the last quarter. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after acquiring an additional 290,153 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its position in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock valued at $21,877,000 after purchasing an additional 135,969 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.